Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes

被引:10
作者
Tong, Yan [1 ]
Huang, Jian Qing [1 ]
Chen, Yang [1 ]
Tu, Mei [1 ]
Wang, Wei [1 ]
机构
[1] Fujian Med Univ, Longyan Affiliated Hosp 1, Longyan, Fujian, Peoples R China
关键词
liraglutide; sitagliptin; bowel preparation quality; gastrointestinal discomfort; gastrointestinal motility; DOSE POLYETHYLENE-GLYCOL; GLUCOSE; COLONOSCOPY; EXENATIDE; SUPERIOR; MOTILITY; TRANSIT;
D O I
10.3389/fphar.2023.1176206
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) profoundly affect the gastrointestinal motor system, which may increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms. Hence, this observational study mainly aimed to assess the influence of GLP-1 RAs liraglutide and DPP-4i sitagliptin on bowel preparation in type 2 diabetes (T2DM). Method: This observational study consecutively enrolled T2DM scheduled for a colonoscopy. Participants were prospectively separated into the liraglutide group (n = 120), sitagliptin group (n = 120), and control group (n = 120) based on the current hypoglycemic regimen. 3L split-dose polyethylene glycol regimens were used for bowel preparation. Experienced gastrointestinal endoscopists conducted colonoscopies. Lawrance Bowel-Preparation Tolerability Questionnaire and Boston Bowel Preparation Scale (BBPS) were conducted to assess bowel cleaning quality, tolerability, and safety. Results: The incidence of inadequate bowel cleaning was 17.5% in the liraglutide group, 20.5% in the sitagliptin group, and 21.7% in the control group. The difference among the three groups was not statistically significant (p = 0.927). Meanwhile, there were no significant differences in the mean BBPS, cecal intubation time, and polyp-detecting rates among the three groups (all p > 0.0.05). Nausea, vomiting, and bloating scores were increased in the liraglutide group compared with the other two groups (p < 0.05), whereas most were mild or very mild. Subgroup analyses showed that the incidence of inadequate bowel cleaning in T2DM with diabetic peripheral neuropathy (DPN) was increased in the liraglutide group compared with the sitagliptin group (61.3% vs. 32.1%, p = 0.022) and control group (61.3% vs. 32.8%, p = 0.025). Conclusion: GLP-1RA liraglutide or DPP-4i sitagliptin did not significantly increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms during bowel preparation. Liraglutide may increase the incidence of inadequate bowel preparation in patients with DPN. This study reveal that more attention and aggressive bowel preparation regimens should be given to the T2DM with DPN.
引用
收藏
页数:9
相关论文
共 50 条
[31]   Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial [J].
Lin, Lu ;
Xu, Xiangjin ;
Yu, Yunjie ;
Ye, Hongjiang ;
He, Xiaoqiong ;
Chen, Shengping ;
Chen, Xaingqi ;
Shao, Zhulin ;
Chen, Pin .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) :1428-1434
[32]   ALBIGLUTIDE Glucagon-Like Peptide GLP-1 Receptor Agonist Treatment of Type 2 Diabetes [J].
Rosenstock, Julio ;
Stewart, Murray W. .
DRUGS OF THE FUTURE, 2010, 35 (09) :701-712
[33]   3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy [J].
El Sanadi, Caroline E. ;
Ji, Xinge ;
Kattan, Michael W. .
ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (21)
[34]   Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin [J].
Tatosian, Daniel A. ;
Guo, Ying ;
Schaeffer, Andrea K. ;
Gaibu, Natalia ;
Popa, Serghei ;
Stoch, Aubrey ;
Langdon, Ronald B. ;
Kauh, Eunkyung A. .
DIABETES THERAPY, 2013, 4 (02) :431-442
[35]   Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin [J].
Daniel A. Tatosian ;
Ying Guo ;
Andrea K. Schaeffer ;
Natalia Gaibu ;
Serghei Popa ;
Aubrey Stoch ;
Ronald B. Langdon ;
Eunkyung A. Kauh .
Diabetes Therapy, 2013, 4 :431-442
[36]   Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus [J].
Neumiller, Joshua J. ;
Campbell, R. Keith .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (18) :1515-1525
[37]   Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study [J].
Takeshita, Yumie ;
Kita, Yuki ;
Tanaka, Takeo ;
Goto, Hisanori ;
Nakano, Yujiro ;
Teramura, Chisato ;
Enyama, Yasufumi ;
Takamura, Toshinari .
JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (06) :965-974
[38]   The Therapeutic Potential of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Peripheral Neuropathy [J].
Panou, Theodoros ;
Gouveri, Evanthia ;
Popovic, Djordje S. ;
Papazoglou, Dimitrios ;
Papanas, Nikolaos .
DIABETES THERAPY, 2025, :1077-1105
[39]   Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus [J].
Guyton, Justinne ;
Jeon, Michelle ;
Brooks, Amie .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (21) :1739-1748
[40]   Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide [J].
Schiavon, Michele ;
Visentin, Roberto ;
Gobel, Britta ;
Riz, Michela ;
Cobelli, Claudio ;
Klabunde, Thomas ;
Dalla Man, Chiara .
DIABETES OBESITY & METABOLISM, 2021, 23 (08) :1795-1805